Regulation in Cell Cycle via p53 and PTEN Tumor Suppressors

Authors

  • Yasuko Kitagishi Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan
  • Satoru Matsuda Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan
  • Akari Minami Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan
  • Yuna Ono Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan
  • Atsuko Nakanishi Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan
  • Yasunori Ogura Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan

DOI:

https://doi.org/10.17140/CSMMOJ-1-101

Keywords:

p53, PTEN, AKT, MDM2, Protein interaction, Protein degradation, Cell signaling, Cell cycle regulation

Abstract

One of the target effectors of p53 transcription factor is the Phosphatase and Tensin homologue deleted on chromosome 10 (PTEN) which has protein phosphatase activity and lipid phosphatase activity that antagonizes PI3K activity. Cells that lack PTEN have constitutively higher levels of PIP3 and activated downstream targets. Both p53 and PTEN are tumor suppressors that act by inhibiting cell cycle progression and promoting apoptosis. Germline mutations in p53 and PTEN cause Li-Fraumeni syndrome and Cowden syndrome, respectively. The p53 cooperates with PTEN, which might be an essential blockage in development of cancers. PTEN protects p53 from MDM2-mediated degradation, whereas p53 can enhance the transcription of PTEN. This review summarizes the function of PTEN and p53 in cell cycle regulation. We will also discuss the role of PTEN signaling through its interaction with p53 and MDM2 pathways for the potential implications in the cell cycle regulation.

References

Perry ME and Levine AJ. Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Dev. 1993; 3(1): 50-54.

Wang B, Xiao Z, Ko HL, and Ren EC. The p53 response ele-ment and transcriptional repression. Cell Cycle. 2010; 9(5): 870- 879. doi: 10.4161/cc.9.5.10825

Murray-Zmijewski F, Slee EA, and Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol. 2008; 9(9): 702-712. doi: 10.1038/nrm2451

Song MS, Salmena L, and Pandolfi PP. The functions and reg-ulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5): 283-296. doi: 10.1038/nrm3330

Merritt MA and Cramer DW. Molecular pathogenesis of en-dometrial and ovarian cancer. Cancer Biomark. 2010; 9(1-6): 287-305. doi: 10.3233/CBM-2011-0167

Hobert JA and Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009; 11(10): 687-694. doi: 10.1097/ GIM.0b013e3181ac9aea

Maehama T and Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999; 9(4): 125-128. doi: http://dx.doi.org/10.1016/S0962- 8924(99)01519-6

Chen Z, Trotman LC, Shaffer D et al. Crucial role of p53- dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436(7051): 725-730. doi: 10.1038/ nature03918

Kim J, Eltoum IE, Roh M, Wang J, and Abdulkadir SA. In-teractions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet. 2009; 5(7): e1000542. doi:

1371/journal.pgen.1000542 10. Blanco-Aparicio C, Renner O, Leal JF, and Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007; 28(7): 1379-1386. doi: 10.1093/carcin/bgm052

Faesen AC, Dirac AM, Shanmugham A, Ovaa H, Perrakis A, and Sixma TK. Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regula-tion by GMP-synthetase. Mol Cell. 2011; 44(1): 147-159. doi: 10.1016/j.molcel.2011.06.034

Sacco JJ, Coulson JM, Clague MJ, and Urbé S. Emerg ing roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 2010; 62(2): 140-157. doi: 10.1002/iub.300

Cully M, You H, Levine AJ, and MAKTW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesism. Nat Rev Cancer. 2006; 6(3): 184-192. doi: 10.1038/nrc1819

Okumura N, Yoshida H, Kitagishi Y, Murakami M, Nishimu-ra Y, and Matsuda S. PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis. Adv Hematol. 2012; 2012: 843085. doi: http://dx.doi.org/10.1155/2012/843085

Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, and Mat-suda S. Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun. 2011; 413(3): 395-399. doi: 10.1016/j.bbrc.2011.08.098

Walden H and Martinez-Torres RJ. Regulation of Parkin E3 ubiquitin ligase activity. Cell Mol Life Sci. 2012; 69(18): 3053- 3067. doi: 10.1007/s00018-012-0978-5

Mueller S, Phillips J, Onar-Thomas A et al. PTEN promoter methylation and activation of the PI3K/AKT/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro On-col. 2012; 14(9): 1146-1152. doi: 10.1093/neuonc/nos140

Faurschou A, Gniadecki R, Calay D, and Wulf HC. TNF-alpha impairs the S-G2/M cell cycle checkpoint and cyclobutane pyrimidine dimer repair in premalignant skin cells: role of the PI3K-AKT pathway. J Invest Dermatol. 2008; 128(8): 2069- 2077. doi: 10.1038/jid.2008.19

Chen Y, Wang BC, and Xiao Y. PI3K: a potential therapeutic target for cancer. J Cell Physiol. 2012; 227(7): 2818-2821.doi: 10.1002/jcp.23038

Choi Y, Zhang J, Murga C et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/AKT pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene. 2002; 21(34): 5289-5300. doi: 10.1038/sj.onc.1205650

Petrella BL, and Brinckerhoff CE. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Cancer Biol Ther. 2009; 8(14): 1389-1401. doi: 10.4161/cbt.8.14.8880

Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, and Ogawa K. Neoplastic hepatocyte growth associated with cy clin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog. 2006; 45(12): 901-913. doi: 10.1002/mc.20204

Andrés-Pons A, Gil A, Oliver MD, Sotelo NS, and Pulido R. Cytoplasmic p27Kip1 counteracts the pro-apoptotic function of the open conformation of PTEN by retention and destabilization of PTEN outside of the nucleus. Cell Signal. 2012; 24(2): 577- 587. doi: 10.1016/j.cellsig.2011.10.012

Planchon SM, Waite KA, and Eng C. The nuclear affairs of PTEN. J Cell Sci. 2008; 121(Pt 3): 249-253. doi: 10.1242/ jcs.022459

Pei D, Zhang Y, and Zheng J. Regulation of p53: a collabora-tion between MDM2 and Mdmx. Oncotarget. 2012; 3(3): 228- 235.

Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, and Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 2010; 22(1): 64-69. doi: 10.1097/CCO.0b013e328333bf00

Vousden KH and Prives C. Blinded by the Light: The Grow-ing Complexity of p53. Cell. 2009; 137: 413–431. doi: 10.1016/j. cell.2009.04.037

Kruse JP and Gu W. Modes of p53 regulation. Cell. 2009; 137: 609–622. doi: 10.1016/j.cell.2009.04.050

Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003; 3(2): 117-130.

Lo PK, Lee JS, and Sukumar S. The p53-p21WAF1 check-point pathway plays a protective role in preventing DNA rerep-lication induced by abrogation of FOXF1 function. Cell Signal. 2012; 24(1): 316-324. doi: 10.1016/j.cellsig.2011.09.017

Puszyński K, Hat B, and Lipniacki T. Oscillations and bi-stability in the stochastic model of p53 regulation. J Theor Biol. 2008; 254(2): 452-465. doi: 10.1016/j.jtbi.2008.05.039

Eitel JA, Bijangi-Vishehsaraei K, Saadatzadeh MR et al. EN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle. 2009; 8(6): 896-901. doi: 10.4161/cc.8.6.7899

Zhang M. PTEN in action: coordinating with p53 to regulate maspin gene expression. Cell Cycle. 2009; 8(8): 1112-1113. doi: 10.4161/cc.8.8.8506

Mayo LD and Donner DB. A phosphatidylinositol 3-kinase/ AKT pathway promotes translocation of MDM2 from the cyto-plasm to the nucleus. Proc Natl Acad Sci U S A. 2001; 98(20): 11598-11603.

Quevedo C, Kaplan DR, and Derry WB. AKT-1 regulates DNA-damage-induced germline apoptosis in C. elegans. Curr Biol. 2007; 17(3): 286-292. doi: http://dx.doi.org/10.1016/j. cub.2006.12.038

Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, and Hung MC. HER-2/neu induces p53 ubiquitination via AKT-mediated MDM2 phosphorylation. Nat Cell Biol. 2001; 3(11): 973-982. doi: 10.1038/ncb1101-973

Ming M and He YY. PTEN in DNA damage repair. Cancer Lett. 2012; 319(2): 125-129. doi: 10.1016/j.canlet.2012.01.003

Bonavida B and Baritaki S. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry. Crit Rev Oncog. 2011; 16(3-4): 211-226. doi: 10.1615/Crit-RevOncog.v16.i3-4.50

Wang X and Jiang X. MDM2 and MdmX partner to regu-late p53. FEBS Lett. 2012; 586(10): 1390-1396. doi: 10.1016/j. febslet.2012.02.049

Levav-Cohen Y, Haupt S, and Haupt Y. MDM2 in growth signaling and cancer. Growth Factors. 2005; 23(3): 183-192. doi: 10.1080/08977190500196218

Mayo LD and Donner DB. The PTEN, MDM2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27(9): 462-467. doi: http://dx.doi.org/10.1016/S0968-0004- (02)02166-7

Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, and Es-che H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene. 1999; 18(17): 2728-2738. doi: 10.1038/ sj.onc.1202626

Zheng T, Meng X, Wang J et al. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem. 2010; 111(1): 218-228. doi: 10.1002/jcb.22691

Mayo LD, Dixon JE, Durden DL, Tonks NK, and Donner DB. PTEN protects p53 from MDM2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002; 277(7): 5484-5489. doi: 10.1074/jbc.M108302200

Sen P, Mukherjee S, Ray D, and Raha S. Involve-ment of the AKT/PKB signaling pathway with disease pro-cesses. Mol Cell Biochem. 2003; 253(1-2): 241-246. doi: 10.1023/A:1026020101379

de Lima Mde D, Marques YM, Alves Sde M Jr et al. MDM2, P53, P21WAF1 and pAKT protein levels in genesis and be-haviour of adenoid cystic carcinoma. Cancer Epidemiol. 2009; 33(2): 142-146. doi: 10.1016/j.canep.2009.04.016

Li AG, Piluso LG, Cai X, Wei G, Sellers WR, and Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006; 23(4): 575-587. doi: http://dx.doi. org/10.1016/j.molcel.2006.06.028

Vu BT and Vassilev L. Small-molecule inhibitors of the p53- MDM2 interaction. Curr Top Microbiol Immunol. 2011; 348: 151-172. doi: 10.1007/82_2010_110

Bixby D, Kujawski L, Wang S, and Malek SN. The pre-cli nical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle. 2008; 7(8): 971-979. doi: 10.4161/cc.7.8.5754

Amodio N, Scrima M, Palaia L et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol. 2010; 177(5): 2622-2634. doi: 10.2353/ajpath.2010.091075

Valiente M, Andrés-Pons A, Gomar B et al. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/ threonine kinases. J Biol Chem. 2005; 280(32): 28936-28943. doi: 10.1074/jbc.M504761200

Torres J and Pulido R. The tumor suppressor PTEN is phos-phorylated by the protein kinase CK2 at its C terminus. Impli-cations for PTEN stability to proteasome-mediated degrada-tion. J Biol Chem. 2001; 276(2): 993-998. doi: 10.1074/jbc. M009134200

Wu W, Wang X, Zhang W et al. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem. 2003; 278(30): 28258-28263. doi: 10.1074/jbc.M303318200

Li Y, Ozaki T, Kikuchi H, Yamamoto H, Ohira M, and Na-kagawara A. A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner. Oncogene. 2008; 27(26): 3700-3709. doi: 10.1038/sj.onc.1211032

ShinadAKTsukiyama T, Sho T, Okumura F, Asaka M, and Hatakeyama S. RNF43 interacts with NEDL1 and regulates p53- mediated transcription. Biochem Biophys Res Commun. 2011; 404(1): 143-147. doi: 10.1016/j.bbrc.2010.11.082

Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul. 2011; 51(1): 37-49.

Downloads

Published

2014-04-09

How to Cite

Yasuko Kitagishi, Satoru Matsuda, Akari Minami, Yuna Ono, Atsuko Nakanishi, & Yasunori Ogura. (2014). Regulation in Cell Cycle via p53 and PTEN Tumor Suppressors. Cancer Studies and Molecular Medicine , 1(1), 1–7. https://doi.org/10.17140/CSMMOJ-1-101

Issue

Vol. 1 No. 1 (2014): Volume 1 Issue 1 2014

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.

Similar Articles

<< < 1 2 3 > >> 

You may also start an advanced similarity search for this article.